ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy PDF Print E-mail
Monday, 07 June 2010 11:08
ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.

The patent comes nearly two years after it was developed by University of Tennessee Health Science Center researchers Arnold Postlethwaite and Andrew Kang and acquired by ArGentis. ArGentis, a Memphis-based specialty biopharmaceutical company, began the patent process and Phase I trials of ARG201 in 2008.

The treatment is for systemic sclerosis, a form of scleroderma, a widespread connective tissue disease that affects the skin, blood vessels, muscles and internal organs. The disease affects about 100,000 people in the U.S. If ARG201 proves successful through its trial, it would become one of the first therapies for patients who have had the disease between three and 10 years, says Ted Townsend, COO of ArGentis.

“This is an unmet medical need and it would be first in class from a commercialization standpoint,” he says.

Source: Memphis Business Journal
 
More articles :

» Vitamins for Scleroderma

is a class of diseases in which your skin and organs tighten and harden. This autoimmune condition occurs when your body produces an excess of , a protein that comprises your connective tissues. Scleroderma may affect the skin on your hands and...

» Pressure and Pain In Systemic Sclerosis/ Scleroderma

Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, Christopher P Denton, Ariane Herrick, Nuria Navarro-Coy, Howard Collier, Lorraine Loughrey, Sue Pavitt, Heidi J Siddle, Jonathan Wright, Philip S Helliwell, Paul Emery, Anthony C RedmondStudy...

» Unite Against Scleroderma

{gallery}unite{/gallery}

» Nutrition & Dietary Supplements

A comprehensive treatment plan for may include a range of complementary and alternative therapies. Individuals with Scleroderma tend to have deficiencies in many vitamins and minerals. Ask your team of health care providers about the best ways to...

» A Simple Blood Test Could Hold The Clue...

In a recent press release, the reported that a simple blood test could hold the clue and may even save lives. is a common condition, especially in teenagers, affecting approximately 10 million people in the UK. It can vary from being mild to very...

» Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine

Patients with effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers...